Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.39 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.39 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.39 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | PTPRA | P18433 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL3454252 | 1.00 | KDM4E (0.44) | KDM4ETSHRPTPRAHPGDHSD17B10 | |
| Cadaverine Tartrate SCHEMBL27323460 | 1.00 | KDM4E (0.44) | KDM4ETSHRPTPRAHPGDHSD17B10 | |
| Cadaverine Tartrate SCHEMBL29594030 | 1.00 | KDM4E (0.44) | KDM4ETSHRPTPRAHPGDHSD17B10 | |
| Cadaverine Tartrate SCHEMBL5874249 | 0.84 | ALDH1A1 (0.63) | KDM4EPTPRAHPGDHSD17B10CYP1A2 | |
| Cadaverine Tartrate SCHEMBL28081412 | 0.84 | ALDH1A1 (0.63) | KDM4EPTPRAHPGDHSD17B10CYP1A2 | |
| Cadaverine Tartrate SCHEMBL5874237 | 0.84 | ALDH1A1 (0.63) | KDM4EPTPRAHPGDHSD17B10CYP1A2 | |
| Quinoxaline SCHEMBL8072146 | 0.84 | ALDH1A1 (0.50) | KDM4EHPGDHSD17B10CYP1A2ALDH1A1 | |
| Phenazine SCHEMBL27905609 | 0.82 | MAPT (0.54) | KDM4ETSHRHPGDHSD17B10CYP1A2 | |
| Quinoxaline SCHEMBL27455075 | 0.81 | ALDH1A1 (0.48) | KDM4EHPGDHSD17B10CYP1A2ALDH1A1 | |
| Quinoxaline SCHEMBL27455074 | 0.81 | ALDH1A1 (0.48) | KDM4EHPGDHSD17B10CYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2734206-A1 | FIXED DOSE COMBINATION OF BIMATOPROST AND BRIMONIDINE | Allergan, Inc. (US) | 2014-05-28 | — | — | EP | disclosed |
| WO-2013013143-A1 | FIXED DOSE COMBINATION OF BIMATOPROST AND BRIMONIDINE | ALLERGAN, INC. (US) | 2013-01-24 | — | — | WO | disclosed |
| CN-102711471-A | Methods of treating or preventing acute erythema | GALDERMA PHARMA SA | 2012-10-03 | — | — | CN | disclosed |
| CN-102512356-A | Intraocular drug delivery systems | ALLERGAN INC | 2012-06-27 | — | — | CN | disclosed |
| CN-101902913-A | Pre-surgical treatment | GALDERMA LAB INC | 2010-12-01 | — | — | CN | disclosed |
| EP-2200617-A1 | IMPROVED BRIMONIDINE COMPOSITIONS FOR TREATING ERYTHEMA | Galderma Laboratories L.P. (US) | 2010-06-30 | — | — | EP | disclosed |
| CN-101588770-A | Intraocular Drug Delivery System | ALLERGAN INC (US) | 2009-11-25 | — | — | CN | disclosed |
| WO-2009032223-A1 | IMPROVED BRIMONIDINE COMPOSITIONS FOR TREATING ERYTHEMA | GALDERMA LABORATORIES L.P. (US) | 2009-03-12 | — | — | WO | disclosed |
| CN-1033327-C | Process for preparing tricyclotriazolo derivatives and their use | TORAY INDUSTRIES (JP) | 1996-11-20 | — | — | CN | disclosed |
| CN-1066849-A | Three ring triazolo derivatives, its Manufacturing approach and use | TORAY INDUSTRIES (JP) | 1992-12-09 | — | — | CN | disclosed |